NEW MILTON, United Kingdom & BOSTON–Genetix Group plc, the cancer diagnostic and biopharmaceutical technologies group (www.genetix.com), announces the opening of an office in Japan, Genetix KK. To support the opening and operation, Genetix has hired Eiji Takagi, President Genetix KK, Masahiro Tateno, Sales Director Genetix KK and Katsumi Katayama Support Director Genetix KK.

“We’re excited about the prospect of expanding our activity in this important market – until now Genetix has been represented in Japan through independent distributors,” states Terry Pizzie, Director of Global Commercial Operations. “Eiji, Masahiro and Katsumi have all previously held similar positions at analytical instrument firm, Biacore KK, which they founded and grew to be one the most successful in the Biacore family. I’m excited to welcome to the team and am confident Genetix KK will become an integral part of our global success.”

The new office address:

Genetix KK

Imperial Hotel Tower 15F

1-1-1 Uchisaiwaicho Chiyoda-KU

Tokyo, 100-0011 Japan

Tel: 81-3-3507-5736

Fax: 81-3-3507-5601

About Genetix

Genetix (www.genetix.com) delivers the competitive edge in cell identification and selection from discovery to diagnosis. Genetix technologies are bringing new efficiencies to biopharmaceutical and biomarker research from target discovery through to clinical diagnosis. We continually deliver technological breakthroughs to increase our customers’ productivity and success. Genetix customer base includes many of the world’s leading biopharmaceutical, cytogenetic and cancer pathology groups.

Genetix is quoted on the AIM (symbol: GTX) and is based in New Milton, Hampshire, UK with offices in the US, UK and Germany.